Eli Lilly (NYSE: LLY) has been one of the top-performing healthcare megacap stocks of the past decade. Eli Lilly is ...

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

In this video interview, Jim Kremidas, executive director, Association for MultiSite Research Corporations (AMRC), discusses ...

New research compared the effect of semaglutide vs. tirzepatide on weight loss over a 72 week period. Here's what the study ...

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad ...

Billions of dollars worth of U.S. biomanufacturing plant development has been announced, and site selection will likely be ...

DIA, a global non-profit organization of life sciences professionals, will induct four Fellows of DIA and recognize six recipients of Global Inspire Awards and America's Inspire Awards on June 15 as ...

It’s the most prescribed antibiotic in the United States, used by tens of millions of people every year to treat bacterial ...

Researchers are trying to better understand how co-mutations and PD-L1 expression impact response to single-agent KRAS G12C ...

At ASCO, researchers presented results of Phase I trials evaluating combinations of KRAS G12C inhibitors, EGFR inhibitors, and chemotherapy in colorectal cancer.

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...